comparemela.com

Page 3 - கொள்ளை விண்டர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |PureTech Health PLC Announcements | PureTech Health PLC: PureTech Acquires Alivio and Oral IL-22 Candidate

Investegate |PureTech Health PLC Announcements | PureTech Health PLC: PureTech Acquires Alivio and Oral IL-22 Candidate
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Investegate |PureTech Health PLC Announcements | PureTech Health PLC: PureTech s Gelesis Presents Plenity Data at AACE

Investegate |PureTech Health PLC Announcements | PureTech Health PLC: PureTech s Akili Secures $160M in Financing

Investegate |PureTech Health PLC Announcements | PureTech Health PLC: New PureTech Research Published in Nature Journal

  Preclinical research suggests that restoring lymphatic flow in the brain has the potential to address a range of neurodegenerative diseases, such as Alzheimer s and Parkinson s diseases, and associated neuroinflammation   Additionally, research found that improving lymphatic flow could enhance the efficacy of antibody therapies against aberrant proteins, potentially opening a new avenue for disease management   PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ( PureTech or the Company ), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the publication of preclinical research in Nature which suggests that enhancing meningeal lymphatic drainage could improve clinical outcomes for Alzheimer s disease, either alone or in combination with passive immunotherapies such as antibodies directed at amyloid b

PureTech Announces Annual Results for Year Ended December 31, 2020

PureTech Announces Annual Results for Year Ended December 31, 2020 By Staff 2 seconds ago Strong capital base and cash runway extended into the first quarter of 2025, with PureTech level cash and cash equivalents of $443.4 million as of March 31, 2021 1 ($349.4 million as of December 31, 2020 2) and consolidated cash and cash equivalents of $486.5 million as of March 31, 2021 3 ($403.9 million as of December 31, 2020 4) Advancement of Wholly Owned Pipeline with four clinical trial initiations and one successful readout, with three clinical trials ongoing Significant milestones across PureTech’s Founded Entities including one FDA Clearance for Marketing, two European Marketing Authorizations, initiation of a Phase 3 program, $247.8 million raised in 2020 5 and $473.2 million raised in the 2021 post-period

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.